A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

NCT05137262 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

12

Enrollment

OTHER

Sponsor class

Conditions

Urothelial Carcinoma
Bladder Cancer

Interventions

OTHER: Abiraterone acetate
DRUG: Durvalumab
DRUG: Methotrexate
DRUG: Vinblastine
DRUG: Doxorubicin Hydrochloride
DRUG: Cisplatin

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]